Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO(R) Clinical Data, at RSNA and SUO Meetings
(TSX:PRN),(NASDAQ:PROF), TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, announced today the upcoming launch of its TULSA-AI(R) Volume Reduction module for optimizing the treatment of patients with benign […]